Immunohistochemical Assay For Detecting Expression Of Programmed Death Ligand 1 (Pd-L1) In Tumor Tissue

Patent No. EP2981821 (titled "Immunohistochemical Assay For Detecting Expression Of Programmed Death Ligand 1 (Pd-L1) In Tumor Tissue") was filed by Merck Sharp & Dohme on Mar 31, 2014. The application was issued on Nov 3, 2021.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
FORSYTHESep 19, 2019J A KEMP

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP2981821

MERCK SHARP & DOHME
Application Number
EP14778739A
Filing Date
Mar 31, 2014
Status
Patent Maintained As Amended
Oct 1, 2021
Publication Date
Nov 3, 2021